X4 Pharmaceuticals
XFOR
X4 Pharmaceuticals (XFOR) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$3.47
- EPS estimate
- −$3.94
- EPS surprise
- +11.88%
- Revenue surprise
- +21.82%
- Revenue
- $2.0M
- Revenue estimate
- $1.6M
- Reported
- Aug 8, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 8, 2025 | −$3.94 | −$3.47 | +11.88% | $2.0M | SEC |
| Q1 2025 | May 1, 2025 | −$3.55 | $0.04 | +101.13% | $28.8M | SEC |
| Q4 2024 | Mar 25, 2025 | −$5.28 | −$6.00 | −13.64% | $1.4M | SEC |
| Q3 2024 | Nov 13, 2024 | −$5.14 | −$5.40 | −5.00% | $560,000.00 | SEC |
| Q2 2024 | Aug 8, 2024 | −$0.21 | $13.50 | +6399.58% | $563,000.00 | SEC |
| Q1 2024 | May 7, 2024 | −$4.63 | −$7.80 | −68.52% | $0.00 | SEC |
| Q4 2023 | Mar 21, 2024 | −$4.37 | −$3.00 | +31.37% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$4.47 | −$0.30 | +93.28% | $0.00 | SEC |
| Q2 2023 | Aug 10, 2023 | −$4.87 | −$9.90 | −103.42% | $0.00 | SEC |
| Q1 2023 | May 4, 2023 | −$6.38 | −$4.80 | +24.71% | $0.00 | SEC |
| Q4 2022 | Mar 21, 2023 | −$8.10 | −$8.70 | −7.41% | $0.00 | SEC |
| Q3 2022 | Nov 3, 2022 | −$9.00 | −$7.80 | +13.33% | $0.00 | SEC |
| Q2 2022 | Aug 4, 2022 | −$19.00 | −$18.00 | +5.26% | $0.00 | SEC |
| Q1 2022 | May 12, 2022 | −$18.04 | −$21.60 | −19.71% | $0.00 | SEC |
| Q4 2021 | Mar 17, 2022 | −$20.23 | −$37.20 | −83.90% | $0.00 | SEC |
| Q3 2021 | Nov 4, 2021 | −$21.45 | −$22.80 | −6.29% | $0.00 | SEC |
| Q2 2021 | Aug 3, 2021 | −$22.16 | −$22.20 | −0.17% | $0.00 | SEC |
| Q1 2021 | May 6, 2021 | −$25.15 | −$39.00 | −55.07% | $0.00 | SEC |
| Q4 2020 | Mar 4, 2021 | −$27.09 | −$27.30 | −0.77% | $0.00 | SEC |
| Q3 2020 | Nov 5, 2020 | −$22.67 | −$26.10 | −15.14% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did X4 Pharmaceuticals (XFOR) last report earnings?
X4 Pharmaceuticals last reported on Aug 8, 2025, covering fiscal Q2 2025.
Did XFOR beat earnings estimates?
Yes. X4 Pharmaceuticals reported EPS of −$3.47 for Q2 2025 against a −$3.94 estimate — a 11.88% beat.
How much revenue did XFOR report last quarter?
X4 Pharmaceuticals reported $2.0M in revenue for Q2 2025, against a consensus estimate of $1.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.